Streetbeat News

IMVT

Immunovant, Inc.

Industry

Biotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Open

19.40

Mkt cap

3.3B

Volume

911K

High

19.52

P/E Ratio

-7.45

52-wk high

35.97

Low

18.70

Div yield

N/A

52-wk low

17.65

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a $29 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 5:02 pm

Citigroup analyst Samantha Semenkow maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $33.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 2:03 pm

Immunovant reported Q1 losses of $(0.57) per share, missing the analyst consensus estimate of $(0.45) by 26.67%. This is a 62.86% decrease over losses of $(0.35) per share from the same period last year. The company's cash and cash equivalents of $330M is expected to fund operations into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:22 am

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Immunovant (NASDAQ:IMVT) and raised the price target from $27 to $33.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 11:01 am

Immunovant Inc's (NASDAQ:IMVT) FcRn strategy gains momentum as analysts view the ADHERE study as a de-risking factor for CIDP clinical development. The study was conducted by Argenx SE (NASDAQ:ARGX). Stifel has increased the price target for Immunovant from $28 to $34, and HC Wainwright has revised its price target from $27 to $29. The positive ADHERE data supports the autoantibody hypothesis in CIDP, suggesting that most CIDP patients could benefit from an FcRn inhibitor.

Portfolio Pulse from Vandana Singh

July 18, 2023 | 6:39 pm

Over the past 3 months, 9 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. The average price target for the stock is $26.67, an increase of 1.29% from the previous average price target of $26.33. Out of the 9 analysts, 8 have given a bullish rating while 1 has given a somewhat bearish rating.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 1:00 pm

Stifel analyst Alex Thompson maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $34.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 12:23 pm

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $27 to $29.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:14 am

Several stocks recorded significant movements in Monday's pre-market trading session. Acumen Pharmaceuticals, argenx SE, BridgeBio Pharma, Zai Lab Limited, Lilium N.V., TeraWulf Inc., Quantum-Si incorporated, Immunovant, MorphoSys AG, and Activision Blizzard all saw changes in their share prices. Notably, Activision Blizzard's shares gained 4.3% after Sony and Microsoft Corp reached a 10-year deal to keep 'Call of Duty' games on PlayStation consoles.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 11:27 am

Immunovant's stock is trading lower due to profit taking after a rally following the release of its Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 6:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.